Earnings History Data for CytomX Therapeutics, Inc. (CTMX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	AH		CTMX	CytomX Therapeutics, Inc.	77.57	0.07	-0.16	0.04	CytomX GAAP EPS of $0.07 beats by $0.23, revenue of $33.4M beats by $16.3M [11/7/2024 4:37 PM]	1.10	0.10 (10.00%)	1.16	0.16 (16.00%)	0.98 - 5.85	2,320,198	1,100,000	481,341
CytomX GAAP EPS of $0.07 beats by $0.23, revenue of $33.4M beats by $16.3M [11/7/2024 4:37 PM] Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result [Nov-06-24 07:52AM] CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [2024-11-07 04:10PM] CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [2024-11-08 02:32AM] CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates [Nov-07-24 05:55PM] CytomX Therapeutics: Q3 Earnings Snapshot [Nov-07-24 04:49PM]
08-08-2024	AH		CTMX	CytomX Therapeutics, Inc.	98.18	-0.08	-0.07	-0.02	CytomX GAAP EPS of -$0.08 misses by $0.01, revenue of $25.11M beats by $5.12M [8/8/2024 4:42 PM]	1.22	0.04 (2.97%)	1.20	0.02 (1.69%)	1.04 - 5.85	1,124,734	660,000	942
CytomX GAAP EPS of -$0.08 misses by $0.01, revenue of $25.11M beats by $5.12M [8/8/2024 4:42 PM]
08-05-2024	AH		CTMX	CytomX Therapeutics, Inc.	295.94	0.17	-0.03	-0.05	CytomX GAAP EPS of $0.17 beats by $0.24, revenue of $41.46M beats by $19.74M [5/8/2024 4:34 PM]	2.04	-2.16 (-51.43%)	2.72	-1.47 (-35.08%)	1.04 - 5.85	32,968,471	28,500,000	6,355,522
CytomX slides after early data for Amgen-partnered cancer drug [5/9/2024 11:33 AM] CytomX GAAP EPS of $0.17 beats by $0.24, revenue of $41.46M beats by $19.74M [5/8/2024 4:34 PM]
11-03-2024	AH		CTMX	CytomX Therapeutics, Inc.	171.49	0.01	0.02	-0.42	CytomX reports Q4 results [3/11/2024 4:20 PM]	2.15	-0.36 (-14.54%)	2.02	-0.49 (-19.52%)	1.04 - 2.86	1,740,617	3,110,000	215,403
CytomX reports Q4 results [3/11/2024 4:20 PM] CytomX falls as Bristol Myers ends deal for cancer therapy [3/12/2024 1:26 PM]
07-11-2023	AH		CTMX	CytomX Therapeutics, Inc.	84.13	0.04	-0.17	-0.35	CytomX GAAP EPS of $0.04 beats by $0.21, revenue of $26.38M beats by $12.97M [11/7/2023 4:41 PM]	1.27	-0.01 (-0.78%)	1.29	0.01 (0.78%)	1.04 - 3.02	300,822	220,000	5,155
CytomX GAAP EPS of $0.04 beats by $0.21, revenue of $26.38M beats by $12.97M [11/7/2023 4:41 PM]
08-08-2023	AH		CTMX	CytomX Therapeutics, Inc.	112.11	-0.02	-0.19	-0.37	CytomX Non-GAAP EPS of -$0.02 beats by $0.18, revenue of $24.72M beats by $10.98M [8/8/2023 4:44 PM]	1.64	-0.05 (-2.96%)	1.68	-0.01 (-0.59%)	1.17 - 3.02	354,326	240,000	1,019
CytomX Non-GAAP EPS of -$0.02 beats by $0.18, revenue of $24.72M beats by $10.98M [8/8/2023 4:44 PM]
09-05-2023	AH	4:10 PM ET (May 9)	CTMX	CytomX Therapeutics, Inc.	112.59	-0.05	-0.16	-0.37	CytomX GAAP EPS of -$0.05 beats by $0.06, revenue of $23.5M beats by $3.59M [5/9/2023 5:58 PM]	1.82	0.10 (5.81%)	1.72	0.0 (0.00%)	1.17 - 3.02	1,633,101	340,000	1,433
CytomX GAAP EPS of -$0.05 beats by $0.06, revenue of $23.5M beats by $3.59M [5/9/2023 5:58 PM]
27-03-2023	AH	4:10 PM ET (Mar 27)	CTMX	CytomX Therapeutics, Inc.	148.69	-0.42	-0.21	-0.40	CytomX GAAP EPS of -$1.51 misses by $0.24, revenue of $53.16M misses by $18.91M [3/27/2023 4:17 PM]	1.51	-0.28 (-15.64%)	1.49	-0.30 (-16.76%)	1.17 - 3.02	2,900,128	1,140,000	125,379
CytomX GAAP EPS of -$1.51 misses by $0.24, revenue of $53.16M misses by $18.91M [3/27/2023 4:17 PM] CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies [3/28/2023 11:39 AM]
08-11-2022	AH	4:15 PM ET (Nov 8)	CTMX	CytomX Therapeutics, Inc.	82.44	-0.35	-0.32	-0.35	CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M [11/8/2022 5:11 PM]	1.23	0.0 (0.00%)	1.21	-0.02 (-1.63%)	1.17 - 7.53	506,822	260,000	44,487
CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M [11/8/2022 5:11 PM] CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting [Nov-07-22 04:15PM] CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-08-22 04:10PM]
04-08-2022	AH	4:15 PM ET (Aug 4)	CTMX	CytomX Therapeutics, Inc.	94.83	-0.37	-0.36	-0.30	CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21M [8/4/2022 4:36 PM]	1.67	0.04 (2.45%)	1.58	-0.05 (-3.07%)	1.19 - 7.53	1,421,093	1,280,000	22,093
CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21M [8/4/2022 4:36 PM] CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences [Aug-03-22 08:00AM] CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update [Aug-04-22 04:15PM]
05-05-2022	AH	4:15 PM ET (May 5)	CTMX	CytomX Therapeutics, Inc.	119.03	-0.37	-0.35	-0.26	CytomX GAAP EPS of -$0.37 misses by $0.01, revenue of $17.13M misses by $4.12M [5/5/2022 4:25 PM]	1.62	0.02 (0.93%)	1.74	0.13 (8.07%)	1.52 - 8.95	844,019	1,510,000	1,215
CytomX GAAP EPS of -$0.37 misses by $0.01, revenue of $17.13M misses by $4.12M [5/5/2022 4:25 PM] CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update [May-05-22 04:15PM] CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates [May-05-22 06:25PM]
01-03-2022	AH	4:15 PM ET (Mar 1)	CTMX	CytomX Therapeutics, Inc.	262.95	-0.40	-0.22	-0.31	CytomX GAAP EPS of -$1.30 misses by $0.13, revenue of $69.57M misses by $5.85M [3/1/2022 4:50 PM]	4.03	0.49 (13.84%)	3.82	0.28 (7.91%)	3.52 - 10.05	963,016	500,000	1,016
CytomX GAAP EPS of -$1.30 misses by $0.13, revenue of $69.57M misses by $5.85M [3/1/2022 4:50 PM] CytomX stock soars 16% as Q4 revenue rises 20% Y/Y [3/2/2022 1:43 PM] Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates [Feb-28-22 05:15PM] CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference [Feb-28-22 08:00AM] CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update [Mar-01-22 04:15PM] CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates [Mar-01-22 05:45PM] CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript [Mar-02-22 01:00AM]
04-11-2021	AH	4:15 PM ET (Nov 4)	CTMX	CytomX Therapeutics, Inc.	370.09	-0.35	-0.30	-0.32	CytomX EPS beats by $0.65, misses on revenue [11/4/2021 4:18 PM]	6.57	0.59 (9.87%)	5.98	0.0 (0.00%)	4.28 - 10.05	671,173	730,000	35,525
CytomX EPS beats by $0.65, misses on revenue [11/4/2021 4:18 PM] CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update [Nov-04-21 04:15PM] CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates [Nov-04-21 06:05PM] CytomX Therapeutics, inc (CTMX) Q3 2021 Earnings Call Transcript [Nov-05-21 07:30AM]
05-08-2021	AH	4:15 PM ET (Aug 5)	CTMX	CytomX Therapeutics, Inc.	373.16	-0.30	-0.26	-0.34	CytomX EPS in-line, misses on revenue [8/5/2021 4:55 PM]	5.22	-0.56 (-9.76%)	5.55	-0.24 (-4.15%)	5.20 - 10.05	1,221,070	460,000	2,671
CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1) [Aug-04-21 08:00AM] CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update [Aug-05-21 04:15PM] CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates [Aug-05-21 05:35PM]
06-05-2021	AH	4:15 PM ET (May 6)	CTMX	CytomX Therapeutics, Inc.	559.09	-0.26	-0.29	0.26	CytomX EPS beats by $0.06, misses on revenue [5/6/2021 4:27 PM]	8.56	0.41 (4.97%)	8.25	0.10 (1.23%)	6.25 - 15.44	585,078	1,600,000	308,261
CytomX EPS beats by $0.06, misses on revenue [5/6/2021 4:27 PM] CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update [May-06-21 04:15PM] CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates [May-06-21 06:05PM] CytomX Therapeutics, Inc. to Host Earnings Call [May-06-21 03:15PM]
24-02-2021	AH	4:15 PM ET (Feb 24)	CTMX	CytomX Therapeutics, Inc.	526.76	-0.31	-0.35	-0.79	CytomX beats on revenue [2/24/2021 4:30 PM]	7.90	-0.14 (-1.74%)	8.50	0.46 (5.72%)	3.60 - 15.44	603,543	835,088	410
CytomX beats on revenue [2/24/2021 4:30 PM] CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update [Feb-24-21 04:15PM]
05-11-2020	AH	4:15 PM ET (Nov 5)	CTMX	CytomX Therapeutics, Inc.	310.87	-0.32	-0.36	-0.52	CytomX EPS beats by $0.11, beats on revenue [11/5/2020 4:38 PM]	7.00	-0.07 (-0.99%)	7.48	0.41 (5.80%)	3.60 - 15.44	267,067	425,719	2,275

06-08-2020	AH	4:10 PM ET (Aug 6)	CTMX	CytomX Therapeutics, Inc.	338.45	-0.34	0.34	-0.64	CytomX EPS misses by $0.83, misses on revenue [8/6/2020 4:29 PM]	7.85	0.30 (3.97%)	7.15	-0.40 (-5.30%)	3.60 - 15.44	216,340	472,016	12,470